Andrew J. Phimister

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2

Sungjoon Kim, Nanxin Li, M. Warmuth, 2013, Journal of medicinal chemistry.

Prevention of naphthalene‐induced pulmonary toxicity by glutathione prodrugs: Roles for glutathione depletion in adduct formation and cell injury

C. Plopper, H. Nagasawa, A. Buckpitt, 2005, Journal of biochemical and molecular toxicology.

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).

P. McNamara, S. Joseph, B. Laffitte, 2017, Journal of medicinal chemistry.

Conformation-dependent Stability of Junctophilin 1 (JP1) and Ryanodine Receptor Type 1 (RyR1) Channel Complex Is Mediated by Their Hyper-reactive Thiols*

H. Takeshima, P. Allen, I. Pessah, 2007, Journal of Biological Chemistry.

Developmental Exposure to Polychlorinated Biphenyls Interferes with Experience-Dependent Dendritic Plasticity and Ryanodine Receptor Expression in Weanling Rats

R. Stackman, T. Ward, I. Pessah, 2008, Environmental Health Perspectives.

Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis (NASH).

I. Sancho-Martinez, P. McNamara, S. Joseph, 2020, Journal of medicinal chemistry.